TherapeuticsMD Inc (TXMD) Raised to Hold at Zacks Investment Research
TherapeuticsMD Inc (NASDAQ:TXMD) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Thursday.
According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “
TXMD has been the topic of a number of other reports. Noble Financial restated a “buy” rating and issued a $17.50 price target on shares of TherapeuticsMD in a report on Monday, July 11th. Jefferies Group reiterated a “buy” rating on shares of TherapeuticsMD in a research note on Wednesday, June 8th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/therapeuticsmd-inc-txmd-raised-to-hold-at-zacks-investment-research.html
Shares of TherapeuticsMD (NASDAQ:TXMD) opened at 6.32 on Thursday. TherapeuticsMD has a 52 week low of $5.18 and a 52 week high of $11.26. The stock has a 50 day moving average of $7.02 and a 200-day moving average of $7.65. The stock’s market capitalization is $1.24 billion.
TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by $0.01. The firm had revenue of $4.40 million for the quarter, compared to analyst estimates of $5.63 million. During the same quarter in the prior year, the company earned ($0.16) EPS. The business’s quarterly revenue was down 8.3% on a year-over-year basis. On average, equities research analysts expect that TherapeuticsMD will post ($0.43) EPS for the current year.
TherapeuticsMD, Inc is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination.
Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.